Skip to main
QURE

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 36%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

uniQure is a biotechnology company with a positive outlook as it focuses on developing gene therapies for genetic and other devastating diseases, such as hemophilia, Huntington's disease, and cardiovascular diseases. The company has a strong pipeline of products and services, including collaborations with Bristol Myers Squibb. Additionally, its financials show a stable cash runway and disciplined portfolio management. Clinical risks and reliance on the success of its lead development candidate, AMT-130, remain key factors to monitor.

Bears say

uniQure is a promising biotechnology company with a strong focus on developing effective gene therapies for various genetic diseases. However, the negative outlook stems from several key risks that could hinder the company's potential for success. These risks include potential delays in the U.S. regulatory approval for its lead product candidate AMT-130, which could impact its timeline and revenue projections. Additionally, the company heavily relies on this candidate for success, which poses significant financial risks in case of failure. Finally, uniQure faces competition and a volatile stock market, which could affect its overall commercial success.

uniQure (QURE) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 36% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 11 analysts, uniQure (QURE) has a Buy consensus rating as of May 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.